Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of PRD001 in Healthy Participants and Patients with Mild Hyper-LDL/Fatty Liver
NCT07034183Phase 1Recruiting
- Sponsor
- PRD Therapeutics
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRD001 in hypercholesterolemia and fatty liver disease (FLD) (4 arms), sponsored by PRD Therapeutics. Primary endpoint: Incidence of treatment-emergent Adverse Events at 42 days. Started Jun 2025; status: recruiting.
02
Drugs
PRD001
03
Conditions
hypercholesterolemiafatty liver disease (FLD)
Beyond the preview
Go deeper on NCT07034183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034183.